How to optimize current treatment of genotype 2 hepatitis C virus infection

The standard of care (SOC) for hepatitis C virus (HCV) genotype 2 is pegylated interferon (PEG‐IFN) plus ribavirin (RBV). Even though most patients can be cured with this therapy after 24 weeks, tailoring treatment can improve its safety and efficacy in special populations. Thus, shortening treatmen...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Liver international 2014-02, Vol.34 (s1), p.13-17
Hauptverfasser: Marciano, Sebastián, Gadano, Adrián C.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 17
container_issue s1
container_start_page 13
container_title Liver international
container_volume 34
creator Marciano, Sebastián
Gadano, Adrián C.
description The standard of care (SOC) for hepatitis C virus (HCV) genotype 2 is pegylated interferon (PEG‐IFN) plus ribavirin (RBV). Even though most patients can be cured with this therapy after 24 weeks, tailoring treatment can improve its safety and efficacy in special populations. Thus, shortening treatment together with a weight‐based RBV dosing approach has been considered satisfactory in patients with positive predictors of response. With the development of the direct antiviral agents (DAAs), shorter, better tolerated and more efficient treatments for HCV genotype 2 will become available, including interferon‐free regimens. Until these new treatments are released, the decision to treat patients with HCV genotype 2 with currently approved drugs or to wait for future options must be made, taking into account the stage of fibrosis.
doi_str_mv 10.1111/liv.12399
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1496893862</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1490753070</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3969-b3f88a92e26614ea04e0f5af4c3f8226d29f9db4d7b6ace4c50a5f6ef4789a983</originalsourceid><addsrcrecordid>eNqNkMtOwzAQRS0E4lFY8APIS1iE-pE48RJVvESBTYGl5aZjMCRxsB1K-XoChe6QmM2MNGeuNAehfUqOaV_Dyr4dU8alXEPbNM2LhDNO11cz41toJ4RnQqiUGd1EWyzlOSc530ZXF26Oo8Oujba2H4DLzntoIo4edKy_JmfwIzQuLlrADD9Bq6ONNuARfrO-C9g2BspoXbOLNoyuAuz99AG6OzudjC6S8e355ehknJRcCplMuSkKLRkwIWgKmqRATKZNWvYLxsSMSSNn03SWT4UuIS0zojMjwPTfSC0LPkCHy9zWu9cOQlS1DSVUlW7AdUHRVIpC8kKw_6Akz3oVpEePlmjpXQgejGq9rbVfKErUl2bVa1bfmnv24Ce2m9YwW5G_XntguATmtoLF30lqfHn_G5ksL2yI8L660P5FiZznmXq4OVfXk4nMr264euCf7IqV7g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1490753070</pqid></control><display><type>article</type><title>How to optimize current treatment of genotype 2 hepatitis C virus infection</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Marciano, Sebastián ; Gadano, Adrián C.</creator><creatorcontrib>Marciano, Sebastián ; Gadano, Adrián C.</creatorcontrib><description>The standard of care (SOC) for hepatitis C virus (HCV) genotype 2 is pegylated interferon (PEG‐IFN) plus ribavirin (RBV). Even though most patients can be cured with this therapy after 24 weeks, tailoring treatment can improve its safety and efficacy in special populations. Thus, shortening treatment together with a weight‐based RBV dosing approach has been considered satisfactory in patients with positive predictors of response. With the development of the direct antiviral agents (DAAs), shorter, better tolerated and more efficient treatments for HCV genotype 2 will become available, including interferon‐free regimens. Until these new treatments are released, the decision to treat patients with HCV genotype 2 with currently approved drugs or to wait for future options must be made, taking into account the stage of fibrosis.</description><identifier>ISSN: 1478-3223</identifier><identifier>EISSN: 1478-3231</identifier><identifier>DOI: 10.1111/liv.12399</identifier><identifier>PMID: 24373073</identifier><language>eng</language><publisher>United States: Blackwell Publishing Ltd</publisher><subject>Algorithms ; Antiviral agents ; Antiviral Agents - adverse effects ; Antiviral Agents - therapeutic use ; cirrhosis ; direct antiviral agents ; Drug Therapy, Combination - methods ; Drug Therapy, Combination - standards ; Genotype ; Hepacivirus - drug effects ; Hepacivirus - genetics ; Hepatitis C - drug therapy ; Hepatitis C virus ; Humans ; Interferon-alpha - therapeutic use ; pegylated interferon ; Polyethylene Glycols - therapeutic use ; predictors of treatment response ; Recombinant Proteins - therapeutic use ; ribavirin ; Ribavirin - therapeutic use ; Standard of Care - trends ; Time Factors ; treatment duration ; Treatment Outcome</subject><ispartof>Liver international, 2014-02, Vol.34 (s1), p.13-17</ispartof><rights>2013 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd</rights><rights>2013 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3969-b3f88a92e26614ea04e0f5af4c3f8226d29f9db4d7b6ace4c50a5f6ef4789a983</citedby><cites>FETCH-LOGICAL-c3969-b3f88a92e26614ea04e0f5af4c3f8226d29f9db4d7b6ace4c50a5f6ef4789a983</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fliv.12399$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fliv.12399$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,782,786,1419,27931,27932,45581,45582</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24373073$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Marciano, Sebastián</creatorcontrib><creatorcontrib>Gadano, Adrián C.</creatorcontrib><title>How to optimize current treatment of genotype 2 hepatitis C virus infection</title><title>Liver international</title><addtitle>Liver Int</addtitle><description>The standard of care (SOC) for hepatitis C virus (HCV) genotype 2 is pegylated interferon (PEG‐IFN) plus ribavirin (RBV). Even though most patients can be cured with this therapy after 24 weeks, tailoring treatment can improve its safety and efficacy in special populations. Thus, shortening treatment together with a weight‐based RBV dosing approach has been considered satisfactory in patients with positive predictors of response. With the development of the direct antiviral agents (DAAs), shorter, better tolerated and more efficient treatments for HCV genotype 2 will become available, including interferon‐free regimens. Until these new treatments are released, the decision to treat patients with HCV genotype 2 with currently approved drugs or to wait for future options must be made, taking into account the stage of fibrosis.</description><subject>Algorithms</subject><subject>Antiviral agents</subject><subject>Antiviral Agents - adverse effects</subject><subject>Antiviral Agents - therapeutic use</subject><subject>cirrhosis</subject><subject>direct antiviral agents</subject><subject>Drug Therapy, Combination - methods</subject><subject>Drug Therapy, Combination - standards</subject><subject>Genotype</subject><subject>Hepacivirus - drug effects</subject><subject>Hepacivirus - genetics</subject><subject>Hepatitis C - drug therapy</subject><subject>Hepatitis C virus</subject><subject>Humans</subject><subject>Interferon-alpha - therapeutic use</subject><subject>pegylated interferon</subject><subject>Polyethylene Glycols - therapeutic use</subject><subject>predictors of treatment response</subject><subject>Recombinant Proteins - therapeutic use</subject><subject>ribavirin</subject><subject>Ribavirin - therapeutic use</subject><subject>Standard of Care - trends</subject><subject>Time Factors</subject><subject>treatment duration</subject><subject>Treatment Outcome</subject><issn>1478-3223</issn><issn>1478-3231</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkMtOwzAQRS0E4lFY8APIS1iE-pE48RJVvESBTYGl5aZjMCRxsB1K-XoChe6QmM2MNGeuNAehfUqOaV_Dyr4dU8alXEPbNM2LhDNO11cz41toJ4RnQqiUGd1EWyzlOSc530ZXF26Oo8Oujba2H4DLzntoIo4edKy_JmfwIzQuLlrADD9Bq6ONNuARfrO-C9g2BspoXbOLNoyuAuz99AG6OzudjC6S8e355ehknJRcCplMuSkKLRkwIWgKmqRATKZNWvYLxsSMSSNn03SWT4UuIS0zojMjwPTfSC0LPkCHy9zWu9cOQlS1DSVUlW7AdUHRVIpC8kKw_6Akz3oVpEePlmjpXQgejGq9rbVfKErUl2bVa1bfmnv24Ce2m9YwW5G_XntguATmtoLF30lqfHn_G5ksL2yI8L660P5FiZznmXq4OVfXk4nMr264euCf7IqV7g</recordid><startdate>201402</startdate><enddate>201402</enddate><creator>Marciano, Sebastián</creator><creator>Gadano, Adrián C.</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7U9</scope><scope>H94</scope></search><sort><creationdate>201402</creationdate><title>How to optimize current treatment of genotype 2 hepatitis C virus infection</title><author>Marciano, Sebastián ; Gadano, Adrián C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3969-b3f88a92e26614ea04e0f5af4c3f8226d29f9db4d7b6ace4c50a5f6ef4789a983</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Algorithms</topic><topic>Antiviral agents</topic><topic>Antiviral Agents - adverse effects</topic><topic>Antiviral Agents - therapeutic use</topic><topic>cirrhosis</topic><topic>direct antiviral agents</topic><topic>Drug Therapy, Combination - methods</topic><topic>Drug Therapy, Combination - standards</topic><topic>Genotype</topic><topic>Hepacivirus - drug effects</topic><topic>Hepacivirus - genetics</topic><topic>Hepatitis C - drug therapy</topic><topic>Hepatitis C virus</topic><topic>Humans</topic><topic>Interferon-alpha - therapeutic use</topic><topic>pegylated interferon</topic><topic>Polyethylene Glycols - therapeutic use</topic><topic>predictors of treatment response</topic><topic>Recombinant Proteins - therapeutic use</topic><topic>ribavirin</topic><topic>Ribavirin - therapeutic use</topic><topic>Standard of Care - trends</topic><topic>Time Factors</topic><topic>treatment duration</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Marciano, Sebastián</creatorcontrib><creatorcontrib>Gadano, Adrián C.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Liver international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Marciano, Sebastián</au><au>Gadano, Adrián C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>How to optimize current treatment of genotype 2 hepatitis C virus infection</atitle><jtitle>Liver international</jtitle><addtitle>Liver Int</addtitle><date>2014-02</date><risdate>2014</risdate><volume>34</volume><issue>s1</issue><spage>13</spage><epage>17</epage><pages>13-17</pages><issn>1478-3223</issn><eissn>1478-3231</eissn><abstract>The standard of care (SOC) for hepatitis C virus (HCV) genotype 2 is pegylated interferon (PEG‐IFN) plus ribavirin (RBV). Even though most patients can be cured with this therapy after 24 weeks, tailoring treatment can improve its safety and efficacy in special populations. Thus, shortening treatment together with a weight‐based RBV dosing approach has been considered satisfactory in patients with positive predictors of response. With the development of the direct antiviral agents (DAAs), shorter, better tolerated and more efficient treatments for HCV genotype 2 will become available, including interferon‐free regimens. Until these new treatments are released, the decision to treat patients with HCV genotype 2 with currently approved drugs or to wait for future options must be made, taking into account the stage of fibrosis.</abstract><cop>United States</cop><pub>Blackwell Publishing Ltd</pub><pmid>24373073</pmid><doi>10.1111/liv.12399</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1478-3223
ispartof Liver international, 2014-02, Vol.34 (s1), p.13-17
issn 1478-3223
1478-3231
language eng
recordid cdi_proquest_miscellaneous_1496893862
source MEDLINE; Access via Wiley Online Library
subjects Algorithms
Antiviral agents
Antiviral Agents - adverse effects
Antiviral Agents - therapeutic use
cirrhosis
direct antiviral agents
Drug Therapy, Combination - methods
Drug Therapy, Combination - standards
Genotype
Hepacivirus - drug effects
Hepacivirus - genetics
Hepatitis C - drug therapy
Hepatitis C virus
Humans
Interferon-alpha - therapeutic use
pegylated interferon
Polyethylene Glycols - therapeutic use
predictors of treatment response
Recombinant Proteins - therapeutic use
ribavirin
Ribavirin - therapeutic use
Standard of Care - trends
Time Factors
treatment duration
Treatment Outcome
title How to optimize current treatment of genotype 2 hepatitis C virus infection
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-05T20%3A27%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=How%20to%20optimize%20current%20treatment%20of%20genotype%202%20hepatitis%20C%20virus%20infection&rft.jtitle=Liver%20international&rft.au=Marciano,%20Sebasti%C3%A1n&rft.date=2014-02&rft.volume=34&rft.issue=s1&rft.spage=13&rft.epage=17&rft.pages=13-17&rft.issn=1478-3223&rft.eissn=1478-3231&rft_id=info:doi/10.1111/liv.12399&rft_dat=%3Cproquest_cross%3E1490753070%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1490753070&rft_id=info:pmid/24373073&rfr_iscdi=true